CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Harmony Biosciences Holdings, Inc. - HRMY CFD

    28.74
    0.42%
    0.14
    Low: 28.41
    High: 29.2
    Market Trading Hours* (UTC) Open now
    Closes on Tuesday at 21:00

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.14
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Harmony Biosciences Holdings Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 28.86
    Open* 28.55
    1-Year Change* -50.73%
    Day's Range* 28.41 - 29.2
    52 wk Range 18.61-62.09
    Average Volume (10 days) 586.15K
    Average Volume (3 months) 17.33M
    Market Cap 1.61B
    P/E Ratio 11.13
    Shares Outstanding 58.57M
    Revenue 541.92M
    EPS 2.47
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 19, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 27, 2023 28.74 -0.12 -0.42% 28.86 29.23 28.36
    Nov 24, 2023 28.86 0.51 1.80% 28.35 29.15 28.35
    Nov 22, 2023 28.40 0.84 3.05% 27.56 28.50 27.56
    Nov 21, 2023 27.41 -0.22 -0.80% 27.63 27.99 27.07
    Nov 20, 2023 27.72 0.75 2.78% 26.97 27.81 26.95
    Nov 17, 2023 26.92 0.96 3.70% 25.96 27.16 25.95
    Nov 16, 2023 25.79 0.64 2.54% 25.15 25.88 24.62
    Nov 15, 2023 25.15 0.29 1.17% 24.86 26.13 24.86
    Nov 14, 2023 25.04 0.09 0.36% 24.95 25.22 24.68
    Nov 13, 2023 24.17 0.89 3.82% 23.28 24.42 23.28
    Nov 10, 2023 23.71 0.95 4.17% 22.76 23.89 22.76
    Nov 9, 2023 23.24 -0.67 -2.80% 23.91 23.91 22.84
    Nov 8, 2023 23.86 0.03 0.13% 23.83 24.38 23.48
    Nov 7, 2023 24.28 0.09 0.37% 24.19 25.01 24.19
    Nov 6, 2023 24.88 -1.08 -4.16% 25.96 25.96 24.54
    Nov 3, 2023 25.86 1.01 4.06% 24.85 26.25 24.85
    Nov 2, 2023 24.58 0.18 0.74% 24.40 25.07 23.98
    Nov 1, 2023 24.49 0.81 3.42% 23.68 24.76 23.51
    Oct 31, 2023 23.47 1.60 7.32% 21.87 23.63 21.87
    Oct 30, 2023 19.65 0.50 2.61% 19.15 19.75 18.97

    Harmony Biosciences Holdings, Inc. Events

    Time (UTC) Country Event
    Thursday, November 30, 2023

    Time (UTC)

    14:00

    Country

    US

    Event

    Harmony Biosciences Holdings Inc at Piper Sandler Healthcare Conference
    Harmony Biosciences Holdings Inc at Piper Sandler Healthcare Conference

    Forecast

    -

    Previous

    -
    Monday, February 19, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Harmony Biosciences Holdings Inc Earnings Release
    Q4 2023 Harmony Biosciences Holdings Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 437.855 305.44 159.742 5.995 0
    Revenue 437.855 305.44 159.742 5.995 0
    Cost of Revenue, Total 83.481 55.518 27.738 1.577 0
    Gross Profit 354.374 249.922 132.004 4.418 0
    Total Operating Expense 317.669 244.058 165.395 151.899 41.439
    Selling/General/Admin. Expenses, Total 140.336 132.027 95.57 80.727 29.067
    Research & Development 70.886 30.367 19.448 69.595 12.372
    Operating Income 120.186 61.382 -5.653 -145.904 -41.439
    Interest Income (Expense), Net Non-Operating -15.669 -23.97 -28.22 -6.073 1.541
    Net Income Before Taxes 104.686 37.428 -36.944 -151.977 -39.898
    Net Income After Taxes 181.468 34.597 -36.944 -151.977 -39.898
    Net Income Before Extra. Items 181.468 34.597 -36.944 -151.977 -39.898
    Net Income 181.468 34.597 -36.944 -151.977 -39.898
    Total Adjustments to Net Income 0 0 -26.904 -35.231 -30.185
    Income Available to Common Excl. Extra. Items 181.468 34.597 -63.848 -187.208 -70.083
    Income Available to Common Incl. Extra. Items 181.468 34.597 -63.848 -187.208 -70.083
    Diluted Net Income 181.468 34.597 -63.848 -187.208 -70.083
    Diluted Weighted Average Shares 61.097 59.2052 56.8906 63.8917 72.7654
    Diluted EPS Excluding Extraordinary Items 2.97016 0.58436 -1.12229 -2.93008 -0.96314
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS 2.97016 0.99257 -0.72436 -2.93008 -0.96314
    Unusual Expense (Income) 0 26.146 22.639
    Other, Net 0.169 0.016 -3.071
    Depreciation / Amortization 22.966
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 134.216 119.126 128.308 117.206 107.028
    Revenue 134.216 119.126 128.308 117.206 107.028
    Cost of Revenue, Total 25.008 20.78 26.885 22.959 18.921
    Gross Profit 109.208 98.346 101.423 94.247 88.107
    Total Operating Expense 87.314 78.703 80.695 105.305 73.912
    Selling/General/Admin. Expenses, Total 47.337 38.673 37.757 35.836 36.362
    Research & Development 14.969 13.289 10.092 40.548 12.668
    Operating Income 46.902 40.423 47.613 11.901 33.116
    Interest Income (Expense), Net Non-Operating -2.776 -2.645 -3.583 -3.99 -3.927
    Other, Net -0.031 0.002 0.073 0.056 0.042
    Net Income Before Taxes 44.095 37.78 44.103 7.967 29.231
    Net Income After Taxes 34.3 29.485 48.509 87.943 23.531
    Net Income Before Extra. Items 34.3 29.485 48.509 87.943 23.531
    Net Income 34.3 29.485 48.509 87.943 23.531
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items 34.3 29.485 48.509 87.943 23.531
    Income Available to Common Incl. Extra. Items 34.3 29.485 48.509 87.943 23.531
    Diluted Net Income 34.3 29.485 48.509 87.943 23.531
    Diluted Weighted Average Shares 60.7439 61.2215 61.6237 61.2076 60.9227
    Diluted EPS Excluding Extraordinary Items 0.56467 0.48161 0.78718 1.4368 0.38624
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.56467 0.48161 0.78718 1.4368 0.38624
    Unusual Expense (Income) 0 0
    Depreciation / Amortization 5.961 5.961 5.962 5.961
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 400.285 284.439 262.891 31.497 86.684
    Cash and Short Term Investments 323.115 234.309 228.631 24.457 83.523
    Cash & Equivalents 243.784 234.309 228.631 24.457 83.523
    Total Receivables, Net 54.74 34.843 22.176 4.255 0
    Accounts Receivable - Trade, Net 54.74 34.843 22.176 4.255 0
    Total Inventory 4.297 4.432 3.823 1.088 0
    Prepaid Expenses 9.347 7.637 6.959 1.436 0.703
    Other Current Assets, Total 8.786 3.218 1.302 0.261 2.458
    Total Assets 673.87 433.443 427.074 106.703 89.282
    Property/Plant/Equipment, Total - Net 2.885 0.82 0.938 1.33 1.576
    Intangibles, Net 160.953 143.919 162.343 72.185 0
    Other Long Term Assets, Total 87.179 4.265 0.902 1.691 1.022
    Total Current Liabilities 78.884 53.775 134.539 19.892 7.231
    Accounts Payable 3.786 1.001 2.556 6.36 1.462
    Accrued Expenses 73.088 49.414 131.669 13.417 5.769
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.01 1.36 0.314 0.115 0
    Total Liabilities 271.032 246.936 329.894 118.288 7.754
    Total Long Term Debt 189.647 189.984 194.25 97.946 0
    Long Term Debt 189.647 189.984 194.25 97.946 0
    Other Liabilities, Total 2.501 3.177 1.105 0.45 0.523
    Total Equity 402.838 186.507 97.18 -11.585 81.528
    Redeemable Preferred Stock 411.277 324.201
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Retained Earnings (Accumulated Deficit) -272.13 -453.598 -488.195 -422.863 -242.674
    Total Liabilities & Shareholders’ Equity 673.87 433.443 427.074 106.703 89.282
    Total Common Shares Outstanding 59.6157 58.8258 56.8906 63.9741 63.8889
    Additional Paid-In Capital 675.118 640.104 585.374
    Current Port. of LT Debt/Capital Leases 2 2
    Short Term Investments 79.331
    Long Term Investments 22.568
    Other Equity, Total -0.151
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 462.998 455.641 418.087 400.285 382.082
    Cash and Short Term Investments 370.674 370.983 343.878 323.115 307.763
    Cash & Equivalents 324.603 317.415 287.962 243.784 261.343
    Total Receivables, Net 67.264 63.812 52.575 54.74 55.065
    Accounts Receivable - Trade, Net 67.264 63.812 52.575 54.74 55.065
    Total Inventory 5.087 4.854 4.09 4.297 3.9
    Prepaid Expenses 14.269 9.442 11.399 9.347 11.246
    Other Current Assets, Total 5.704 6.55 6.145 8.786 4.108
    Total Assets 777.766 760.183 715.092 673.87 643.464
    Property/Plant/Equipment, Total - Net 2.884 2.629 2.854 2.885 3.338
    Intangibles, Net 143.069 149.031 154.992 160.953 166.914
    Other Long Term Assets, Total 101.115 94.231 90.621 87.179 82.85
    Total Current Liabilities 112.408 93.045 85.363 78.884 107.357
    Accounts Payable 6.539 6.563 6.414 3.786 10.049
    Accrued Expenses 84.766 73.321 64.375 73.088 93.937
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 6.103 2.161 8.074 0.01 1.371
    Total Liabilities 296.434 275.011 272.051 271.032 299.58
    Total Long Term Debt 182.131 180.487 185.063 189.647 189.725
    Long Term Debt 182.131 180.487 185.063 189.647 189.725
    Other Liabilities, Total 1.895 1.479 1.625 2.501 2.498
    Total Equity 481.332 485.172 443.041 402.838 343.884
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Additional Paid-In Capital 651.731 694.038 685.716 675.118 664.7
    Retained Earnings (Accumulated Deficit) -169.884 -208.345 -242.645 -272.13 -320.639
    Total Liabilities & Shareholders’ Equity 777.766 760.183 715.092 673.87 643.464
    Total Common Shares Outstanding 58.5719 59.9997 59.9546 59.6157 59.3044
    Current Port. of LT Debt/Capital Leases 15 11 6.5 2 2
    Short Term Investments 46.071 53.568 55.916 79.331 46.42
    Long Term Investments 67.7 58.651 48.538 22.568 8.28
    Other Equity, Total -0.516 -0.522 -0.031 -0.151 -0.178
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 181.468 34.597 -36.944 -151.977 -39.898
    Cash From Operating Activities 144.466 98.557 -2.985 -75.436 -38.799
    Cash From Operating Activities 0.419 0.416 0.394 0.395 0.184
    Amortization 22.966 18.424 9.843 2.815 0
    Non-Cash Items 29.662 44.489 35.35 65.039 1.079
    Cash Interest Paid 16.364 19.83 26.203 4.23 0
    Changes in Working Capital -4.106 0.631 -11.628 8.292 -0.164
    Cash From Investing Activities -141.832 -100.298 -2.002 -127.149 -1.342
    Capital Expenditures -40.172 -100.298 -0.002 -75.149 -1.342
    Other Investing Cash Flow Items, Total -101.66 -2 -52 0
    Cash From Financing Activities 6.841 7.419 209.161 143.769 21.615
    Financing Cash Flow Items 0 -31.452 -36.061 -6.316 -0.185
    Issuance (Retirement) of Stock, Net 8.841 39.371 147.76 50.085 21.8
    Issuance (Retirement) of Debt, Net -2 -0.5 97.462 100 0
    Net Change in Cash 9.475 5.678 204.174 -58.816 -18.526
    Cash Taxes Paid 12.645 2.875
    Deferred Taxes -85.943
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 29.485 181.468 132.959 45.016 21.485
    Cash From Operating Activities 42.559 144.466 117.788 62.583 28.852
    Cash From Operating Activities 0.103 0.419 0.312 0.211 0.117
    Amortization 5.961 22.966 17.005 11.043 5.082
    Non-Cash Items 6.71 29.662 21.292 13.86 5.693
    Cash Interest Paid 5.017 16.364 11.334 7.524 3.829
    Changes in Working Capital 3.742 -4.106 27.899 -7.547 -3.525
    Cash From Investing Activities -1.79 -141.832 -94.937 -62.492 -40.045
    Capital Expenditures 0 -40.172 -40.172 -40.086 -40.045
    Cash From Financing Activities 3.409 6.841 4.183 2.133 1.383
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 3.909 8.841 5.683 3.133 1.883
    Issuance (Retirement) of Debt, Net -0.5 -2 -1.5 -1 -0.5
    Net Change in Cash 44.178 9.475 27.034 2.224 -9.81
    Cash Taxes Paid 12.645
    Other Investing Cash Flow Items, Total -1.79 -101.66 -54.765 -22.406
    Deferred Taxes -3.442 -85.943 -81.679
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Valor Equity Partners Private Equity 18.6967 11218033 0 2023-06-30 LOW
    Marshman Fund Trust ii Corporation 17.7518 10651120 10651120 2023-03-27
    Fidelity Management & Research Company LLC Investment Advisor 9.1171 5470247 -121328 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.9824 4789427 479167 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.9839 3590342 59281 2023-06-30 LOW
    Vivo Capital, LLC Venture Capital 4.3437 2606247 0 2023-06-30 LOW
    HBM Partners AG Investment Advisor 3.5799 2147943 -2397300 2022-12-31 LOW
    Adage Capital Management, L.P. Hedge Fund 2 1200000 -215000 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.9016 1140934 97337 2023-06-30 LOW
    VenBio Partners LLC Private Equity 1.7257 1035396 0 2023-06-30 MED
    Macquarie Investment Management Investment Advisor 1.5025 901528 72859 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 1.4856 891370 791370 2023-06-30 MED
    Citadel Advisors LLC Hedge Fund 1.3348 800860 269053 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 1.2682 760893 168070 2023-06-30 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.2209 732551 -99476 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1022 661306 87681 2023-06-30 LOW
    abrdn Inc. Investment Advisor/Hedge Fund 1.0636 638179 13873 2023-06-30 MED
    Neumeier Poma Investment Counsel LLC Investment Advisor 1.0604 636240 -42475 2023-06-30 LOW
    Morgan Stanley & Co. LLC Research Firm 0.9912 594724 114263 2023-06-30 MED
    International Biotechnology Trust PLC Corporation 0.9508 570500 0 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Harmony Biosciences Holdings, Inc. Company profile

    About Harmony Biosciences Holdings Inc

    Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. The Company’s product, WAKIX (pitolisant), is a molecule with mechanism of action (MOA), designed to histamine signaling in the brain by binding to H3 receptors. It also provides HBS-102, a Melanin Concentrating Hormone Receptor One (MCHR1) antagonist that offers treatment of narcolepsy, including the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations and sleep paralysis.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Harmony Biosciences Holdings Inc revenues increased 91% to $305.4M. Net income applicable to common stockholders totaled $34.6M vs. loss of $63.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest expense, net decrease of 15% to $24M (expense), Other income (expense).

    Industry: Pharmaceuticals (NEC)

    630 W Germantown Pike
    Suite 215
    PLYMOUTH MEETING
    PENNSYLVANIA 19462
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023
    Gold bars

    XAU/USD Latest: Gold advances as weaker data weighs on US yields

    Gold moves higher as softer economic data weighs on US yields and the dollar

    13:43, 17 November 2023

    People also watch

    BTC/USD

    37,356.45 Price
    +0.540% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    15,936.60 Price
    -0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,017.18 Price
    +0.000% 1D Chg, %
    Long position overnight fee -0.0194%
    Short position overnight fee 0.0112%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.61 Price
    +1.200% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading